Pioneers Of Safer Gene Therapies
Discover a carefully selected group of innovative companies developing alternatives to traditional viral vector gene therapies. These stocks represent biotechs working on potentially safer genetic medicine technologies like siRNA and antisense oligonucleotides, handpicked by professional analysts for their pioneering approaches.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
Join Nemo FREE today and unlock every stock.
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
Recent safety setbacks in viral vector gene therapies have created an opportunity for companies developing alternative approaches. This collection focuses on innovators using non-viral technologies like siRNA, antisense oligonucleotides, and CRISPR that may offer safer ways to treat genetic diseases.
What You Need to Know
This is a high-growth, high-risk thematic investment in cutting-edge biotechnology. These companies are developing next-generation genetic medicines that could potentially transform treatment for many diseases, but many are still in development stages with uncertain regulatory paths.
Why These Stocks
These companies were selected for their leadership in non-viral genetic medicine approaches that may gain favor as the market reassesses viral vector risks. They represent diverse technologies and development stages, giving exposure to multiple potential breakthrough platforms in this evolving sector.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+290.42%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 290.42% over the next year.
Stocks Rated Buy by Analysts
17 of 18 assets in this group are rated Buy by professional analysts.
Why You'll Want to Watch These Stocks
Industry Pivot Point
Safety concerns with traditional gene therapies are triggering a major shift in the biotech industry. These companies could be perfectly positioned to capture new investment as the market seeks safer alternatives.
Next-Gen Breakthrough Potential
These pioneers are developing cutting-edge technologies that could transform genetic medicine. Many are working on platforms that could treat previously untouchable diseases without the risks of viral vectors.
Under-the-Radar Opportunity
While media attention has focused on viral vector setbacks, smart money is quietly shifting toward these alternative approaches. These stocks may be undervalued before the broader market fully recognizes the potential shift.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Uncle Sam's Semiconductor Stake
The U.S. government is considering an equity stake in Intel to boost domestic semiconductor manufacturing. This strategic move could create a ripple effect, benefiting other American companies involved in the chip-making industry.
The Cybersecurity Consolidation Wave
Accenture's record-breaking acquisition of CyberCX signals a major consolidation trend in the cybersecurity sector. This move highlights the growing demand for AI-powered security solutions, creating potential opportunities for other specialized cybersecurity firms to benefit from increased investment and M&A activity.
American Chipmakers: A Tariff-Driven Shift
President Trump has threatened to impose tariffs of up to 300% on semiconductors to boost domestic production. This creates a potential investment opportunity in U.S.-based semiconductor companies that stand to gain from a shift toward onshore manufacturing.
Frequently Asked Questions
Everything you need to know about the product and billing.